Jedd Wolchok is apparently not one to rest on his laurels. As the principal investigator on the 024 study that led to approval of the first commercially successful cancer immunotherapy, CTLA-4 checkpoint inhibitor Yervoy (ipilimumab, Bristol-Myers Squibb Co.) as well as several phase III trials investigating the combination of Yervoy and PD-1 checkpoint blocker Opdivo (nivolumab, Bristol-Myers Squibb Co.), Wolchok has done as much as anyone currently working in oncology for patients.